** Shares of cancer therapy developer Greenwich LifeSciences GLSI.O rise 18.8% to $11 premarket
** GLSI says its experimental therapy, GLSI-100, to prevent breast cancer recurrences showed an increased immune response over time in patients during a late-stage study
** The therapy creates an immune response over time, as measured by the increasing injection site reactions with increased vaccinations
** Company says in the preliminary data, the patients reported immune response increased over time from baseline through the 4th- to 6th-month vaccinations
** As of last close, stock has fallen 51.4% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。